A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

    A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
    By Nevan Krogan

    May 19, 2020 at 11:00 AM EDT!
     
    Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. This webinar will describe our efforts to address this challenge by expressing 26 of the 29 SARS-CoV-2 proteins in human cells and identifying the human proteins physically associated with each using affinity-purification mass spectrometry. Among 332 high-confidence SARS-CoV-2-human protein-protein interactions, we identified 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Within a subset of these, multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity.
     
      Registration is complimentary.


    © 2019 H3ABioNet.org
    Terms - Privacy - Policy & Safety - Helpdesk
    The H3ABioNet website content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health
    Image
    © University of Cape Town 2020. All rights reserved.